2026 Interim report
Filed with HKEX · Stock code 2126 · · 73 pages · English
JW (Cayman) Therapeutics Co. Ltd. on 6ix
Earlier from JW (Cayman) Therapeutics
- JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development and Maximize Global Platform Potential
- JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
- JW Therapeutics - Receipt of Breakthrough Therapy Designation for Carteyva in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
- JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
- JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
Later from JW (Cayman) Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Very substantial disposal in relation to the license and assignment agreement
Follow JW (Cayman) Therapeutics into a list and get an email when it puts out news.
Follow JW (Cayman) Therapeutics